

RHYO Options Underwriting Agreement

Melbourne, Australia, 31 March 2026: Rhythm Biosciences Ltd (“RHY”, the “Company” or the “Group”) (ASX: RHY), a transformative, predictive cancer diagnostics technology company confirms that the deadline for exercising RHYO Options is 5:00 pm (Melbourne time) on 31 March 2026 and, to date, and the Company has seen a significant volume of options being exercised.

For clarification, as of the date of this announcement, the Underwriting Agreement with CPS Capital Group Pty Ltd (“CPS”, the “Underwriter”) first announced on 25 February 2026 and set out in the Prospectus dated 30 March 2026 is in place. The Company anticipates issuing the Shortfall Notice to the Underwriter per the original timeline on 2 April 2026, supporting the continued growth of the business through the commercialisation of its novel cancer diagnostic products branded as ColoSTAT® and geneType™. Furthermore, the termination provisions in the Prospectus accurately reflect the executed Underwriting Agreement (and supersede the termination provisions set out in the announcement dated 25 February 2026).

- ENDS -

This announcement was authorised by the Managing Director & CEO of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia
T +61 3 8256 2880
E info@rhythmbio.com

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.